{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+System+Disorders&page=82",
    "query": {
      "condition": "Immune System Disorders",
      "page": 82
    },
    "page_size": 10
  },
  "pagination": {
    "page": 82,
    "page_size": 10,
    "total_count": 21025,
    "total_pages": 2103,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+System+Disorders&page=83&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+System+Disorders&page=81&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T02:55:32.337Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06617325",
      "title": "A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "DZP",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2024-11-21",
      "completion_date": "2028-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-09T02:55:32.337Z",
      "location_count": 63,
      "location_summary": "Avondale, Arizona • Chandler, Arizona • Gilbert, Arizona + 55 more",
      "locations": [
        {
          "city": "Avondale",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06617325"
    },
    {
      "nct_id": "NCT07895576",
      "title": "R34 Asthma Depression",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Asthma",
        "Depression"
      ],
      "interventions": [
        {
          "name": "SAMBA",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Cognitive Behavioral Therapy-Asthma Depression (CBT-AD)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Original SAMBA",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-11-01",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-09T02:55:32.337Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07895576"
    },
    {
      "nct_id": "NCT01987817",
      "title": "Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peanut Allergy"
      ],
      "interventions": [
        {
          "name": "AR101 powder provided in capsules",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo powder provided in capsules",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Aimmune Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "4 Years to 26 Years"
      },
      "enrollment_count": 56,
      "start_date": "2014-02-06",
      "completion_date": "2015-01-07",
      "has_results": true,
      "last_update_posted_date": "2021-11-30",
      "last_synced_at": "2026-11-09T02:55:32.337Z",
      "location_count": 8,
      "location_summary": "Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01987817"
    },
    {
      "nct_id": "NCT01139450",
      "title": "Study of 0417 Ointment in the Treatment of Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "0417",
          "type": "DRUG"
        },
        {
          "name": "Vehicle of 0417 test product",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus Ointment 0.03%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fougera Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 899,
      "start_date": "2008-01",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2014-10-09",
      "last_synced_at": "2026-11-09T02:55:32.337Z",
      "location_count": 1,
      "location_summary": "Melville, New York",
      "locations": [
        {
          "city": "Melville",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01139450"
    },
    {
      "nct_id": "NCT02064374",
      "title": "Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Metformin 500 mg q12h",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir 50 mg q24h",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir 50 mg q12h",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-02",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2014-05-26",
      "last_synced_at": "2026-11-09T02:55:32.337Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02064374"
    },
    {
      "nct_id": "NCT00441818",
      "title": "Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "TNX-650",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tanox",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2006-05",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2008-05-09",
      "last_synced_at": "2026-11-09T02:55:32.337Z",
      "location_count": 2,
      "location_summary": "New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00441818"
    },
    {
      "nct_id": "NCT00123890",
      "title": "Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "GW873140",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2005-06",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2011-03-29",
      "last_synced_at": "2026-11-09T02:55:32.337Z",
      "location_count": 34,
      "location_summary": "Tucson, Arizona • Laguna Beach, California • Long Beach, California + 30 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Laguna Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00123890"
    },
    {
      "nct_id": "NCT05602597",
      "title": "HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory Lymphoma"
      ],
      "interventions": [
        {
          "name": "Itraconazole 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Fluconazole 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Rifampin 600 mg",
          "type": "DRUG"
        },
        {
          "name": "Rabeprazole 40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchmed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 59,
      "start_date": "2022-06-01",
      "completion_date": "2022-08-06",
      "has_results": false,
      "last_update_posted_date": "2024-03-06",
      "last_synced_at": "2026-11-09T02:55:32.337Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05602597"
    },
    {
      "nct_id": "NCT05265910",
      "title": "A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "olopatadine hydrochloride ophthalmic solution 0.7%",
          "type": "DRUG"
        },
        {
          "name": "loratadine 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Tears Naturale",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andover Research Eye Institute",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2021-12-14",
      "completion_date": "2022-04-23",
      "has_results": false,
      "last_update_posted_date": "2022-05-03",
      "last_synced_at": "2026-11-09T02:55:32.337Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05265910"
    },
    {
      "nct_id": "NCT05957913",
      "title": "Effects of Antiviral Therapies on Epstein-Barr Virus Replication",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Truvada (tenofovir/emtricitabine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2023-06-05",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-11-09T02:55:32.337Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05957913"
    }
  ]
}